RBC Bioscience

RBC Bioscience CapEx/OCF

The CapEx to Operating Cash Flow Ratio of RBC Bioscience (6848.TWO) as of Nov 6, 2026 is 18.46 %. In the previous year, CapEx to Operating Cash Flow Ratio was 48.94 % — a change of -62.29% (lower).

CapEx/OCF

18.46 %

YoY

-62.29%

Last updated:

CapEx to Operating Cash Flow Ratio of RBC Bioscience is 2024 18.46 % . CapEx to Operating Cash Flow Ratio of RBC Bioscience was 2023 48.94 % . It decreases by -62.29% lower compared to the previous year.

The RBC Bioscience CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
1,784.53 TWD
Jan 1, 2019
22.62 TWD
Jan 1, 2020
57.57 TWD
Jan 1, 2021
-1,779.18 TWD
Jan 1, 2022
152.16 TWD
Jan 1, 2023
48.94 TWD
Jan 1, 2024
18.46 TWD
The RBC Bioscience CapEx/OCF history
YEARCapEx/OCFYoY
18.46 %-62.29%
48.94 %-67.84%
152.16 %-108.55%
-1,779.18 %-3,190.46%
57.57 %+154.48%
22.62 %-98.73%
1,784.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

CapEx to Operating Cash Flow Ratio of RBC Bioscience is 18.46 % in 2024.

CapEx to Operating Cash Flow Ratio of RBC Bioscience changed from 48.94 % to 18.46 %, representing a -62.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RBC Bioscience

All Key Metrics — RBC Bioscience